Company Filing History:
2 out of 2,893 
1 out of 2,963 
Years Active: 2018-2020
Title: Cammie Lesser: Innovator in Engineered Microbial Cells
Introduction
Cammie Lesser is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of engineered microbial cells. With a total of 2 patents, Lesser's work focuses on innovative methods and compositions that enhance the capabilities of bacteria in delivering therapeutic proteins.
Latest Patents
Cammie Lesser's latest patents include groundbreaking technologies. The first patent, titled "Methods and compositions relating to engineered microbial cells," describes compositions and methods involving engineered bacteria with a modified Type 3 Secretion System (T3SS). This modification allows the bacteria to deliver proteins to the extracellular space, which is a significant advancement over traditional methods that target the intracellular space of cells. The second patent, "Compositions and methods for bacterial delivery of polypeptides," outlines methods for delivering polypeptides to target cells using engineered non-pathogenic bacteria that express a functional T3SS. This technology has a wide range of applications, including therapeutics and cellular reprogramming.
Career Highlights
Throughout his career, Cammie Lesser has worked with prestigious institutions, including The General Hospital Corporation and Harvard College. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in microbial engineering.
Collaborations
Cammie Lesser has collaborated with notable colleagues, including Analise Z Reeves and Amy J Wagers. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Cammie Lesser's contributions to the field of engineered microbial cells demonstrate his commitment to advancing biotechnology. His innovative patents and collaborations highlight the potential of engineered bacteria in therapeutic applications.